Loading...
Retrospective study finds low recurrent VTE and major bleeding rates in patients treated with reduced-dose DOACs, suggesting a need for individualized risk assessment.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: